(Q34132778)

31 July 2017

title

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes (English)

1 reference

31 July 2017

0 references

1 reference

Sriram Krishnaswami

2

1 reference

31 July 2017

Joel Kremer

3

1 reference

31 July 2017

Richard J. Riese

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20732649

21 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20732649

21 June 2024

publication date

1 August 2010

1 reference

full work available at URL

31 July 2017

https://api.elsevier.com/content/article/PII:S1521694210000276?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

https://api.elsevier.com/content/article/PII:S1521694210000276?httpAccept=text/plain

21 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Best Practice & Research: Clinical Rheumatology

21 June 2024

published in

1 reference

31 July 2017

volume

24

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

513-526

1 reference

STAT3 in CD4+ T helper cell differentiation and inflammatory diseases

31 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Jaks and STATs: biological implications

21 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.

21 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes

21 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Defective lymphoid development in mice lacking Jak3

21 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3

21 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Developmental defects of lymphoid cells in Jak3 kinase-deficient mice.

21 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

21 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

21 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders

21 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

21 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts

21 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates

21 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy

21 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models

21 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia

21 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers

21 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients

21 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

21 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis

21 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients

21 June 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2010.02.003

21 June 2024

Identifiers

1 reference

31 July 2017

1 reference